What is Peptide Receptor Radionuclide Therapy (PRRT)?
You may have heard about PRRT – Receptor Radionuclide Therapy (PRRT) – and wondered just what it is.
PRRT is a novel nuclear medicine therapy (the first patients were treated in 1996) for the systemic treatment of metastasized neuroendocrine tumors. These types of tumors include gastroenteropancreatic tumors (socalled GEP-NETs), e.g. arising from the small bowel (often called carcinoid tumors), the pancreas, duodenum or stomach, but also from the large bowel or the lung and many other tissues (socalled diffuse neuroendocrine system).
A handful of medical centers in Europe have been doing PRRT since the mid-1990s (including Basel, Milano, Rotterdam, and Bad Berka). These few centers now have 15 years experience administering PRRT.
A clinical trial on PRRT using Lutetium-177 DOTATATE was begin in the US in 2013.
The Bad Berka treatment center is located in Germany, just south of Weimar. Patient visit information is available at the following link: patient visit information.
You can find additional information on PRRT at PRTTINFO.org.
The information on this website is written by patients for patients, so it’s understandable. The site has a full range of information.
Research reports show that serious long-term side effects occur in less than 3% of patients (n=1,300). One treatment center in the Netherlands reports that the treatment provides an additional 3-6 years of life compared to patients not receiving PRRT.
Again, You can find additional information on PRRT at PRTTINFO.org.